Affordable Access

deepdyve-link
Publisher Website

Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed?

Authors
  • Haycox, Alan
  • Featherstone, Richard
Type
Published Article
Journal
Journal of Medical Economics
Publisher
Informa UK Limited
Publication Date
Jan 01, 2008
Volume
11
Issue
3
Pages
525–539
Identifiers
DOI: 10.3111/13696990802340856
PMID: 19450102
Source
Medline
License
Unknown

Abstract

Since completing this study, the reimbursement costs for beclometasone MDIs have increased significantly (since October 2007) due to the discontinuation of Becotide and Becloforte. As a consequence of this higher acquisition cost for MDI inhalers, the current cost-effectiveness advantages of BAI compared to MDI can be expected to be even greater than that identified in the study.

Report this publication

Statistics

Seen <100 times